MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 18, 2012--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
“Company”), the developer of the novel Biopump™ technology for the
sustained production and delivery of therapeutic proteins in patients
using their own tissue, today announced that Andrew L. Pearlman, Ph.D.,
the Company’s President and CEO, will present a corporate overview at
the 11th Annual Israeli Life Sciences Industry Biomed 2011
Conference taking place at the David Intercontinental Hotel in Tel Aviv,
Israel from May 21-23, 2012. Dr. Pearlman will deliver the Company’s
presentation on Monday, May 21 at 4:30 p.m. (local time) in Hall C.
ILSI-Biomed 2012 follows the success of its previous annual conferences:
last year’s event drew 6,000 industry professionals, engineers and
scientists, with 1,000 participants from 42 countries and more than
2,500 one-on-one meetings. This provides Medgenics with significant
opportunity to showcase before a global audience of relevant industry
leaders its novel, tissue-based technology platform, the Biopump, for
the sustained production and dosing of therapeutic proteins using a
patient’s own tissue.
About Israeli Life Sciences Industry
The Israel Life Science Industry (ILSI) is composed of medical device,
biotechnology, pharmaceutical and medical service companies,
universities and private research institutions, and providers of
services to the industry such as venture capitalists, lawyers,
accountants and incubators. The goal of ILSI is to develop solid
information about the medical research and manufacturing community in
Israel, and to make that information available to political leaders, the
news media, venture capitalists, investment bankers, and the public. It
is exactly this information required by potential investors be it
strategic corporate players or financial investors worldwide. The intent
is to demonstrate that medical research and manufacturing is a major
contributor to Israel’s economy - with unusually great potential for
financial growth and job creation.
Medgenics is developing and commercializing Biopump™, a proprietary
tissue-based platform technology for the sustained production and
delivery of therapeutic proteins using the patient's own dermal skin
biopsy for the treatment of a range of chronic diseases including
anemia, hepatitis and hemophilia, among others. Medgenics believes this
approach has multiple benefits compared with current treatments, which
include regular and costly injections of therapeutic proteins.
Medgenics has three long-acting protein therapy products in development
based on this technology:
EPODURE™ to produce and deliver erythropoietin for many months from a
single administration, has demonstrated elevation and stabilization of
hemoglobin levels in anemic patients for six to more than 36 months in
a Phase I/II dose-ranging trial, and has received approval of a Phase
IIa trial in dialysis patients due to launch in Q2 2012 in Israel. An
Investigational New Drug application has been cleared by the FDA to
initiate a Phase IIb study to evaluate the safety and efficacy of
EPODURE in the treatment of anemia in dialysis patients in the U.S.
INFRADURE™ for sustained production and delivery of interferon-alpha
for use in the treatment of hepatitis is awaiting final approval of
two Phase I/II trials in Israel in hepatitis C, slated to commence in
Q3 2012, and is filed for Orphan Drug Designation with the FDA to
treat hepatitis D.
HEMODURE™ for sustained production and delivery of clotting Factor
VIII therapy for the sustained prophylactic treatment of hemophilia is
now in development.
Medgenics is focused on the development and manufacturing of its
innovative Biopumps, aiming to bring them to market via strategic
partnerships with major pharmaceutical and/or medical device companies.
In addition to treatments for anemia, hepatitis and hemophilia,
Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein
therapy market, which is forecast to reach $132 billion in 2013. Other
potential applications for Biopumps include multiple sclerosis,
arthritis, pediatric growth hormone deficiency, obesity and diabetes.
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private
Securities Litigation Reform Act of 1995, which include all statements
other than statements of historical fact, including (without limitation)
those regarding the Company's financial position, its development and
business strategy, its product candidates and the plans and objectives
of management for future operations. The Company intends that such
forward-looking statements be subject to the safe harbors created by
such laws. Forward-looking statements are sometimes identified by their
use of the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the negative
of such terms and other comparable terminology. All such forward-looking
statements are based on current expectations and are subject to risks
and uncertainties. Should any of these risks or uncertainties
materialize, or should any of the Company's assumptions prove incorrect,
actual results may differ materially from those included within these
forward-looking statements. Accordingly, no undue reliance should be
placed on these forward-looking statements, which speak only as of the
date made. The Company expressly disclaims any obligation or undertaking
to disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result of
these factors, the events described in the forward-looking statements
contained in this release may not occur.
Source: Medgenics, Inc.
Dr. Andrew L. Pearlman, +972 4 902 8900
Marie Fields, 212-838-3777
Adam Michael, Joanne Shears, Jamie Hooper
207 398 7719
Capital Markets UK Ltd. (NOMAD)
David Porter, Richard Thompson
207 444 0800
SVS Securities plc (Joint Broker)
Mattey, Ian Callaway
+44 207 638 5600